Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease is a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated changes. The basis for DAPT in arterial disease is discussed, allowing readers to understand platelet physiology and its relevance to ischemic events. Data on shorter than usual duration of DAPT, and on extended therapy beyond the recommendation of current guidelines is presented in great detail, summarizing a large body of evidence into concrete, relevant recommendation that is readily adaptable by practicing clinicians.
A clinically relevant and updated compendium of data pertaining to this field is also presented, as well as the anticipated trends and innovations likely to occur in the next 3-5 years.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. xi 7. Preface - p. xii 8. Chapter 1. Platelets and arterial disease—initiation, progression, and destabilization of atherosclerotic vascular disease - p. 1 9. Chapter 2. Platelet physiology and pharmacology—relevant considerations for patient care - p. 15 10. Chapter 3. The development of dual antiplatelet therapy: physiologic and clinical implications of multiple pathway inhibition of platelet function - p. 47 11. Chapter 4. Acute coronary syndromes and percutaneous coronary intervention—current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data? - p. 57 12. Chapter 5. Peripheral arterial disease—a different kind of arterial disease? The role of antiplatelet therapy in the prevention and treatment of limb ischemia - p. 79 13. Chapter 6. Cerebrovascular disease—what is the role of dual antiplatelet therapy for the prevention and treatment of ischemic stroke? - p. 91 14. Chapter 7. Competing risks in the duration of dual antiplatelet therapy—the case for shorter treatment - p. 111 15. Chapter 8. Dual antiplatelet therapy may prevent coronary ischemic events beyond one year—the case for extended treatment - p. 131 16. Chapter 9. Clinical risk scores: a tool to understand bleeding and thrombotic risk - p. 145 17. Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade—why it could be a novel paradigm? - p. 167 18. Chapter 11. The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it? - p. 193 19. Chapter 12. A look into the future - p. 201 20. Index - p. 203
Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease is a complete reference containing updated information on the advantages and disadvantages of dual antiplatelet therapy, its duration, composition and anticipated changes. The basis for DAPT in arterial disease is discussed, allowing readers to understand platelet physiology and its relevance to ischemic events. Data on shorter than usual duration of DAPT, and on extended therapy beyond the recommendation of current guidelines is presented in great detail, summarizing a large body of evidence into concrete, relevant recommendation that is readily adaptable by practicing clinicians.
A clinically relevant and updated compendium of data pertaining to this field is also presented, as well as the anticipated trends and innovations likely to occur in the next 3-5 years.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. xi 7. Preface - p. xii 8. Chapter 1. Platelets and arterial disease—initiation, progression, and destabilization of atherosclerotic vascular disease - p. 1 9. Chapter 2. Platelet physiology and pharmacology—relevant considerations for patient care - p. 15 10. Chapter 3. The development of dual antiplatelet therapy: physiologic and clinical implications of multiple pathway inhibition of platelet function - p. 47 11. Chapter 4. Acute coronary syndromes and percutaneous coronary intervention—current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data? - p. 57 12. Chapter 5. Peripheral arterial disease—a different kind of arterial disease? The role of antiplatelet therapy in the prevention and treatment of limb ischemia - p. 79 13. Chapter 6. Cerebrovascular disease—what is the role of dual antiplatelet therapy for the prevention and treatment of ischemic stroke? - p. 91 14. Chapter 7. Competing risks in the duration of dual antiplatelet therapy—the case for shorter treatment - p. 111 15. Chapter 8. Dual antiplatelet therapy may prevent coronary ischemic events beyond one year—the case for extended treatment - p. 131 16. Chapter 9. Clinical risk scores: a tool to understand bleeding and thrombotic risk - p. 145 17. Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade—why it could be a novel paradigm? - p. 167 18. Chapter 11. The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it? - p. 193 19. Chapter 12. A look into the future - p. 201 20. Index - p. 203
